Seelos Therapeutics, Inc. has ongoing preclinical programs, including SLS-004, SLS-006, and SLS-007. It has filed a voluntary petition under chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the Southern District of New York.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Market Closed - OTC Markets Other stock markets 09:32:35 22/04/2026 pm IST			5-day change	1st Jan Change
0.000100 ^USD	-.--%		-.--%	-

29/12	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
21/25/21	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI

Capitalization	1L 86.38T 79.22T 74.99T 1L 96.93L 1L 9L 4L 45.98L 4L 4L 1.6Cr	P/E ratio 2022	-0.98x	P/E ratio 2023	-0.18x
Enterprise value	1.13Cr 96.66L 88.65L 83.91L 1.56Cr 108.48Cr 1.57Cr 11Cr 4.11Cr 51Cr 4.25Cr 4.16Cr 178.78Cr	EV / Sales 2022	-	EV / Sales 2023	1,12,78,456x
Free-Float	88.85%	Yield 2022 *	-	Yield 2023	-

29/12	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
21/25/21	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI
14/25/14	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
15/25/15	Bidding Procedure Approved for Seelos Therapeutics, Inc.	CI
01/25/01	Motion for Asset Sale Filed by Seelos Therapeutics, Inc.	CI
30/25/30	Motion for Case Conversion or Dismissal Filed for Seelos Therapeutics, Inc.	CI
16/24/16	Seelos Therapeutics, Inc. Filed for Bankruptcy	CI
18/24/18	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from S&P TMI Index	CI
15/24/15	Top Midday Decliners	MT
15/24/15	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from NASDAQ Composite Index	CI
27/24/27	Top Midday Decliners	MT
25/24/25	Seelos Therapeutics, Inc. Announces the Signing of A Material Transfer Agreement with the U.S. Army Medical Materiel Development Activity	CI
25/24/25	Sector Update: Health Care Stocks Mixed Late Afternoon	MT

21/23/21	Benchmark Cuts Price Target on Seelos Therapeutics to $1 From $4, Maintains Speculative Buy Rating	MT
21/23/21	Guggenheim Downgrades Seelos Therapeutics to Neutral From Buy	MT
21/23/21	Cantor Fitzgerald Downgrades Seelos Therapeutics to Neutral From Overweight	MT
16/23/16	Cantor Fitzgerald Lowers Price Target on Seelos Therapeutics to $2 From $3, Maintains Overweight Rating	MT
24/23/24	Benchmark Adjusts Price Target on Seelos Therapeutics to $4 From $6, Maintains Buy Rating	MT

Seelos Therapeutics, Inc. Share Price

Equities

SEEL.Q

US81577F4063

Biotechnology & Medical Research

Valuation: Seelos Therapeutics, Inc.

Chart: Seelos Therapeutics, Inc.

Latest news : Seelos Therapeutics, Inc.

Analysts' recommendations: Seelos Therapeutics, Inc.

Press Releases: Seelos Therapeutics, Inc.

Course Extremes

Managers and Directors: Seelos Therapeutics, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Income Statement and Estimates

Annual profits - Rate of surprise

22/24/22	Seelos Therapeutics : Late Filing Notice Form NT 10 Q	PU
25/24/25	Seelos Therapeutics : Announces Second Postponement of its Annual Meeting of Stockholders Form 8 K	PU
25/24/25	Seelos Announces Second Postponement of its Annual Meeting of Stockholders	PR
15/24/15	Seelos Therapeutics : Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over the Counter Market Form 8 K	PU
15/24/15	Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market	PR

1 month	0		0
Current year	0		0.01
1 year	0		0.01
3 years	0		6,374.41
5 years	0		20,121.62
10 years	0		28,761.63

Manager	Title	Age	Since
Raj Mehra CEO	Chief Executive Officer	66	01/01/2019
Michael Golembiewski DFI	Director of Finance/CFO	54	01/09/2021
Gopal Krishna CTO	Chief Tech/Sci/R&D Officer	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
SEELOS THERAPEUTICS, INC.	-.--%	-.--%	-80.00%	-100.00%	136
ARGENX SE	+1.01%	+2.89%	+40.00%	+88.60%	5.07TCr
WUXI APPTEC CO., LTD.	+1.48%	+0.71%	+85.71%	+66.61%	4.86TCr
BIONTECH SE	+0.34%	-1.93%	-3.71%	-11.00%	2.36TCr
INSMED INCORPORATED	+11.66%	-16.81%	+71.22%	+519.33%	2.25TCr
WUXI BIOLOGICS (CAYMAN) INC.	+1.94%	-0.41%	+44.95%	-26.82%	1.75TCr
GENMAB A/S	+3.22%	-1.35%	+29.73%	-40.31%	1.61TCr
AKESO, INC.	-0.99%	+1.72%	+63.52%	+205.52%	1.54TCr
SUMMIT THERAPEUTICS INC.	+1.55%	+8.04%	-24.98%	+1,001.74%	1.45TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+2.58%	+0.88%	+50.20%	-	1.34TCr
Average	+2.28%	-1.77%	+27.66%	+189.30%	2.22TCr
Weighted average by Cap.	+2.34%	-1.41%	+46.18%	+171.09%

	2022	2023
Net sales	-	2.2 1.88 1.72 1.63 3.02 210.86 3.05 20.52 7.99 100.02 8.27 8.09 347.51
Net income	-7.35Cr -6.27Cr -5.75Cr -5.44Cr -10Cr -703.82Cr -10Cr -69Cr -27Cr -333.84Cr -28Cr -27Cr -1.16TCr	-3.79Cr -3.23Cr -2.96Cr -2.8Cr -5.2Cr -362.58Cr -5.25Cr -35Cr -14Cr -171.98Cr -14Cr -14Cr -597.57Cr
Net Debt	45.89L 39.14L 35.9L 33.98L 62.97L 44Cr 63.57L 4.28Cr 1.66Cr 21Cr 1.72Cr 1.69Cr 72Cr	1.12Cr 95.8L 87.86L 83.17L 1.54Cr 107.51Cr 1.56Cr 10Cr 4.07Cr 51Cr 4.21Cr 4.13Cr 177.18Cr